Genmab A/S - Company Announcement: Novel Insights Into HuMax-EGFr Mechanisms Of Action Published In PNAS
Apr 17th 2008Drug InformationEndocrinology
Summary: Genmab has announced that HuMax-EGFr (zalutumumab) inhibits epidermal growth factor receptor signaling by locking epidermal growth factor receptor (EGFr) molecules into a very compact, inactive conformation. The flexibility of the EGFr is central to its role in signaling, and binding of HuMax-EGFr (zalutumumab) results in effective inhibition of cancer cell growth.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
